


The Continuous Innovation Indicators (CII) is a dynamic online platform that utilizes published clinical trial data to track progress for 12 cancer types. Outcome measures include effect sizes from individual trials and Evidence-Scores (E-Scores), a novel metric that can track cumulative progress against cancer over time. The CII is an objective data resource that can help stakeholders determine which investments in cancer research form the building blocks for progress against cancer. The CII can:

- Assess how long it takes for basic research to impact the treatment landscape
- Determine whether differences in long-term impact correlate with grant awards
- Measure research impact – quantifying how successes have translated across cancers
- Identify unmet needs and detect gaps in progress
- Inform strategic grant portfolio management

Figure 1. Measuring Investigator Impact Using the Continuous Innovation Indicators



By linking grant-funded publications to successful clinical studies in the CII, it is possible to assess how long it takes for basic research to measurably influence the treatment landscape and determine whether differences in long-term impact correlate with grant characteristics, such as the time to impact across grant types. Additionally, these quantitative analyses can unearth successful grantee achievements to showcase.

The CII platform, accessible at [www.scoringprogress.org](http://www.scoringprogress.org), facilitates a more nuanced approach to interpreting a treatment's utility over time, reveals unmet needs, and tracks progress within and between cancer types. By supporting a broad range of value assessment models, such as impact analysis, the CII improves evidence-based and dynamic estimates of value and can demonstrate return on investment.